公开(公告)号：EP3813877A1

公开(公告)日：2021-05-05

申请号：EP19803135.3

申请日：2019-05-13

申请人： Oncoimmune, Inc. ,  Children's Research Institute, Children's National Medical Center

发明人： LIU, Yang ,  ZHENG, Pan ,  FLORES, Rhonda ,  CHOU, Hung-Yen ,  XUE, Zhihong ,  YE, Peiying ,  DEVENPORT, Martin

IPC分类号： A61K39/395

公开(公告)号：EP3373910A1

公开(公告)日：2018-09-19

申请号：EP16864923.4

申请日：2016-11-09

申请人： Children's Research Institute, Children's National Medical Center

发明人： LIU, Yang ,  WANG, Yin ,  LIU, Yan ,  BAILEY, Christopher ,  ZHENG, Pan

IPC分类号： A61K9/127 ,  A61K31/395 ,  A61K35/74 ,  A61K38/08 ,  A61K38/12

CPC分类号： A61K9/1271 ,  A61K9/1277 ,  A61K35/74 ,  A61K38/164 ,  A61K47/6911 ,  A61P35/02 ,  A61P37/02

摘要： A liposomal drug formulation for treating a disease in a patient characterized by overexpression of HIF-1α and/or HIF-2α includes a plurality of liposomes in a pharmaceutically acceptable carrier. The liposomes encapsulate echinomycin and are made from a peglyated phospholipid, a neutral phosphoglyceride, and a sterol. The PEGylated liposomes may be used to treat proliferative diseases, leukemia, cancer, autoimmune diseases and graft-versus-host disease.

公开(公告)号：EP3921339A2

公开(公告)日：2021-12-15

申请号：EP20753142.7

申请日：2020-02-05

申请人： Oncoimmune Inc. ,  Children's Research Institute, Children's National Medical Center

发明人： LIU, Yang ,  ZHENG, Pan ,  WANG, Xu ,  DEVENPORT, Martin

IPC分类号： C07K14/705 ,  A61K39/00 ,  A61K38/00 ,  G01N33/53 ,  G01N33/00

公开(公告)号：EP3794104A1

公开(公告)日：2021-03-24

申请号：EP19802592.6

申请日：2019-05-20

申请人： Children's Research Institute, Children's National Medical Center

发明人： BOLLARD, Catherine, Mary ,  CRUZ, Conrad Russell, Y. ,  HANLEY, Patrick

IPC分类号： C12M3/02 ,  C12M3/00

公开(公告)号：EP3337491A1

公开(公告)日：2018-06-27

申请号：EP16837853.7

申请日：2016-08-18

申请人： Children's Research Institute, Children's National Medical Center

发明人： LIU, Yang ,  WANG, Yin

IPC分类号： A61K35/28 ,  A61P37/00 ,  A61P37/06 ,  C12N5/0789

CPC分类号： A61K35/28 ,  A61K31/7105 ,  A61K38/08 ,  A61K38/1709 ,  A61K48/005 ,  A61K2300/00 ,  A61P35/02 ,  A61P37/06

摘要： A method of preventing the development of GvHD or reducing the severity of GvHD in a mammalian subject receiving an allogeneic hematopoietic stem cell (HSC) transplant includes administering to the subject a pharmaceutical composition comprising an active agent that inhibits the biological activity or expression of hypoxia-inducible factor-1a (HIF-1a) or hypoxia-inducible factor-2a (HIF-2a), wherein the active agent is administered in an amount effective for preventing or reducing the severity GvHD in the subject.

公开(公告)号：EP3515489A1

公开(公告)日：2019-07-31

申请号：EP17851784.3

申请日：2017-09-19

申请人： Oncoimmune, Inc. ,  Children's Research Institute, Children's National Medical Center

发明人： LIU, Yang ,  DEVENPORT, Martin ,  ZHENG, Pan ,  WU, Wei ,  DU, Xuexiang ,  LIU, Mingyue ,  TANG, Fei

IPC分类号： A61K39/395 ,  A61K39/00 ,  A61K38/00 ,  C07K14/00